Anzalone Christopher Richard, Chief Executive Officer, sold 50,000 shares of the Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in an exchange that happened on April 3rd. The stock was sold at an average price of $19.30 per share, amounting to a transaction worth $965,000. The sale was made public in a document filed with the SEC. Additionally, Chief Operating Officer GIVEN BRUCE D sold 42,500 shares of this stock in a transaction that took place on March 1st. The stock was sold at an average price of $19.99 per share, for a total exchange amounting to $849,575. After the transaction, the Chief Operating Officer GIVEN BRUCE D currently holds 644,606 shares of the company’s stock, which is worth approximately $11809182.
With this stock price’s latest movement, it is now -18.18% away from its 1-year high and 190.49% higher than its 1-year low price. In the past seven days, the stock price volatility for Arrowhead Pharmaceuticals, Inc. was 4.28%, whereas its volatility in the past 30 days has been 4.13%. This public company’s stock also has a beta score of 2.21. When the beta value is less/more than 1, it can imply that the stock is less/more volatile than the wider stock market – a metric that traders will surely be keeping tabs on.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) most recently published its quarterly earnings results. The firm posted $0.13 earnings per share (EPS) for the three-month period, missing analysts’ consensus estimate of $0.54 by $0.41. The publicly-traded organization reported revenue of $34.66 million for the quarter, compared to the average analyst forecast calling for $71.60 million, which was missing the analyst consensus estimate.
Shares of Arrowhead Pharmaceuticals, Inc. (ARWR) plunged -3.83%, amounting to a loss of -$0.73 per share, to finish the regular trading session at $18.32 on Friday April 12th, 2019. After beginning the session at $19.25, shares of Arrowhead Pharmaceuticals, Inc. reached as high as $19.35 during the day, while hitting a 1-day low of $18.12. Trade volume reached 1,914,127 shares against this stock’s average daily volume of 1.60M shares, with a total float of 85.86M. As a consequence of the price decrease, Arrowhead Pharmaceuticals, Inc. now has a current market value of 1.67B.
Stryker Corporation (NYSE:SYK) subtracted -1.36% to its trading price by the close of the most recent session, dropping from its previous closing price of $195.33 to $192.67. This stock decreased in value by -1.32% during the last 7-day period, and experienced a loss of -0.35% over the past 30-day period. In the past three months, this stock’s price grew by 20.80% , and added 12.57% to its price during the last six months of trading. SYK demonstrated a yearly price gain of 21.51% , while its year-to-date (YTD) price performance has been up 22.92% . This stock’s price changed by +22.38% compared to its 90-day low, and moved down -3.59% comparing to its 90-day high price.
Have a quick look on short, medium and long-term indicators. According to the Composite Indicator, Trendspotter rated the SYK stock as “Hold”. In the short-term, Stryker Corporation (SYK) has a 20-day average volume of 1,007,690 shares and short-term indicators sets the SYK stock as “ 60% Sell ” on average basis. In the medium-term, SYK stock has a 50-Day average volume of 1,141,360 shares and medium-term indicators gave the average rating of “ 25% Buy ”, while in the long-term period the stock has a 100-Day average volume of 1,392,290 shares. On average, long-term indicators rated the stock as “67% Buy ”. The overall picture from all short, medium and long-term indicators sets the SYK stock as “Hold Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.” on average basis.
Recently, multiple brokerages have sent out reports on SYK. Canaccord Genuity, for example, Reiterated its rating on shares of Stryker Corporation to a “Buy”, while setting a $190 price target on shares of the company’s stock, according to a research note from Wednesday January 30th, 2019. Deutsche Bank Initiated their target price for this stock to $179, while giving the stock a “Buy” rating, as stated in a research report from Thursday, January 3rd, 2019. Evercore ISI, on the other hand, Upgrade a from “In-line ” to “ Outperform” rating on this stock in a research note dated Wednesday, January 2nd, 2019.
In other news related to Stryker Corporation stock, 76.16% shares of SYK held by institutions. The total number of institutions who held the SYK shares was 1,622, according to most recent SEC filling. During the past quarter, total 284,158,950 shares held by institutions with the net change of 354,863 shares. In the meantime, 20 new institutions bought the shares of Stryker Corporation for the first time and 6 institutions sold all their holdings in the company’s common stock. 89 institutions increased their investment in the SYK stock and 78 institutions decreased their investment in the Stryker Corporation (SYK)’s stock during the last quarter.